

A Multicentre, Observational Study to Evaluate the Real-World Outcomes of Palynziq® (Pegvaliase) in Subjects with Phenylketonuria (OPAL)

First published: 19/07/2021

Last updated: 26/11/2025

Study

Ongoing

Administrative details

EU PAS number

EUPAS41426

Study ID

50667

DARWIN EU® study

No

Study countries

☐ Germany

☐ Italy

☐ United States

Study description

A multicentre observational study evaluating data from routine clinical practice in subjects receiving Pegvaliase for the treatment of PKU. Subjects with PKU who are receiving or have been recommended to receive Pegvaliase to treat their PKU are eligible for participation. The study will have an enrolment period of approximately 32 months and a planned subject data collection period of 24 months. Up to 150 subjects will be enrolled across all sites. During the study, relevant medical information will be obtained via review of the subject's medical records. Subjects who consent to participate in the study will be requested to provide relevant PKU disease history, including PKU treatment history, MNT (including medical foods, intact protein foods natural protein sources, and special low protein foods), concomitant medication use, and any patient-centred outcome data collected as part of routine clinical practice. Information on all blood Phe levels available will be collected as well as Pegvaliase dosing and titration information and prescribed dietary protein and MNT.

Study status

Ongoing

Research institutions and networks

Institutions

[University of Naples Federico II](#)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

University of Ulm

☐ Germany

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Educational Institution

University Medical Centre Hamburg-Eppendorf

☐ Germany

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Educational Institution

Hospital/Clinic/Other health care facility

The Medical College of Wisconsin

First published: 01/02/2024

Last updated: 01/02/2024

Institution

BioMarin Pharmaceuticals

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Universitätsklinikum Schleswig-Holstein

First published: 01/02/2024

Last updated: 01/02/2024

Institution

University Hospital Düsseldorf (UKD)

☐ Germany

First published: 21/11/2025

Last updated: 21/11/2025

Institution

Hospital/Clinic/Other health care facility

Universitätsklinikum Münster (UKM) Munster,
Germany

Kreiskliniken Reutlingen Reutlingen, Germany

Universität Leipzig Leipzig, Germany

Universität Gießen Giessen, Germany

Hospital Carl-Thiem-Klinikum Cottbus Cottbus,
Germany

Klinikum Bremen Mitte Bremen, Germany

Universitätsklinikum Zentrum für Kinder und
Jugendmedizin Mainz, Germany

Policlinico S.Orsola Malpighi, AOU di Bologna
Bologna, Italy

Ospedale San Paolo Milano, Italy

University of Kentucky Lexington, KY, United
States

St. Christopher's Hospital for Children Philadelphia,
PA, United States

Oregon Health & Science University Portland, OR,
United States

Indiana University School of Medicine Indianapolis,
IN, United States

Children's Hospital of Pittsburgh Pittsburgh, PA,
United States

University of Texas Southwestern Medical Center

Dallas, TX, United States

University of Texas Houston Medical School

Houston, TX, United States

Emory University Decatur, Georgia, United States

Children's Hospital Colorado Aurora, Colorado,
United States

Tulane University Medical Center New Orleans, LA,
United States

Ann and Robert H. Lurie Children's Hospital of
Chicago Chicago, IL, United States

University of Florida (Gainesville) Gainesville, FL,
United States

Contact details

Study institution contact

165-508 Program Director medinfo@bmrn.com

Study contact

medinfo@bmrn.com

Primary lead investigator

165-508 Program Director

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 09/04/2021

Study start date

Actual: 20/05/2021

Date of final study report

Planned: 31/07/2026

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

BioMarin

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type:

Non-interventional study

Scope of the study:

Other

If 'other', further details on the scope of the study

Provide real-world evidence data on use of Palynziq in PKU

Main study objective:

The efficacy and safety of Pegvaliase has been established in clinical trials as required for regulatory approval. There remains an important need to provide data to prescribers and the phenylketonuria (PKU) community on the real-world usage of Pegvaliase and associated outcomes to support clinical practice optimisation and provide greater understanding of important clinical issues in PKU.

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Observational study on routine clinical practice

Study drug and medical condition

Medicinal product name

PALYNZIQ

Anatomical Therapeutic Chemical (ATC) code

(A16AB19) pegvaliase

pegvaliase

Medical condition to be studied

Phenylketonuria

Population studied

Age groups

- Adolescents (12 to < 18 years)
 - Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Special population of interest

Pregnant women

Estimated number of subjects

150

Study design details

Outcomes

To evaluate outcomes achieved with Pegvaliase in a real-world setting as measured by blood phenylalanine (Phe) level over time. Describe: dosing

intervals and dosing of Pegvaliase in each phase of treatment and length of titration phase, reported MNT in each treatment phase, relationship between changes in reported MNT and blood Phe, co-medications of interest used in each treatment phase, impact of blood Phe on subjects' wellbeing and health-related Quality of Life and impact of blood Phe on socioeconomic parameters.

Data analysis plan

Data will be collected from patients who are receiving Pegvaliase as part of their routine clinical care undertaken by their PKU treating physician. No formal hypothesis testing or inference will be made. The study will use descriptive summary statistics and various statistical analysis methods for longitudinal, repeated measures data for estimation and summarisation of outcomes, including statistical modelling and graphical methods.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

Prospective patient-based data collection, Site’s routine standard of care
patient notes

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No